Important pharmacogenomic aspects in the management of HIV/AIDS

South African Family Practice

Field Value
Title Important pharmacogenomic aspects in the management of HIV/AIDS
Creator Marais, A. Osuch, E. Steenkamp, V. Ledwaba, L.
Subject CYP450; genetic polymorphisms; nucleoside reverse transcriptase inhibitors; non-nucleoside reverse transcriptase inhibitors; protease inhibitors —
Description In managing HIV/AIDS with highly active antiretroviral agents, the historical therapeutic aim remains to maintain the plasma concentrations at a level above the half maximal inhibitory concentration (IC50) required for 50% inhibition in viral replication. Concentration dependent toxicity is often observed in patients with elevated drug exposure and high peak plasma levels in lieu of accurately calculated drug dosages. Similarly low plasma concentrations are frequently witnessed in individuals receiving adequate dosage regimens. Pharmacogenetic variations in drug metabolizing enzymes may contribute to this phenomenon. Over the last decade, knowledge about the role of pharmacogenetics in the treatment and prediction of ARV plasma levels have increased significantly. However, the extent of these genetic variations remain largely unknown in the South African population, which has sparked a renewed enthusiasm for local pharmacogenetic studies.
Publisher AOSIS
Date 2019-03-08
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Peer-reviewed Article —
Format application/pdf
Identifier 10.4102/safp.v61i1.5047
Source South African Family Practice; Vol 61, No 1 (2019): January/February 2078-6204 2078-6190
Language eng
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:
Coverage — — —
Rights Copyright (c) 2019 A. Marais, E. Osuch, V. Steenkamp, L. Ledwaba